Brief: Algernon Announces First Patient Dosed In Phase 2 Ipf And Chronic Cough Human Trial Of Ifenprodil
05/08/2020 13:38
Aug 5 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 IPF AND
CHRONIC COUGH HUMAN TRIAL OF IFENPRODIL
Source text for Eikon: ID:nGNX3zLNGr
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement